Stuart Maudsley | Receptor Pharmacology | Best Researcher Award

Prof. Dr. Stuart Maudsley | Receptor Pharmacology | Best Researcher Award

Senior Fellow/Professor, H. Lee Moffitt Cancer Center, United States

Dr. Stuart Russell Maudsley is a renowned pharmacologist with a distinguished career in receptor biology, specializing in therapeutic precision medicines targeting GPCRs (G-Protein Coupled Receptors). He is currently the Principal Investigator at the Maudsley Lab and a Senior Member at Moffitt Cancer Center. Dr. Maudsley is also a co-founder of HeptOME, focusing on aging-related diseases and metabolic dysfunction. With over two decades of research experience, he has held prominent roles including scientific advisor to the Belgian Superior Health Council, and various leadership roles at Johns Hopkins, the NIH, and VIB. His groundbreaking work includes receptor pharmacology and molecular biology studies aimed at advancing novel treatments for complex human disorders, particularly cancer and neurodegenerative diseases. His career has been recognized globally, earning numerous awards and honors for his contributions to molecular pharmacology.

Profile

Education

Dr. Stuart Russell Maudsley obtained his PhD in Pharmacology from the University of Leeds, UK, where he was awarded the Ackroyd, Brotherton & Brown Scholarship. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, marking the beginning of his illustrious career in receptor pharmacology. Prior to his PhD, Dr. Maudsley earned a First-Class B.Sc. in Pharmacology from the same institution. During his academic tenure, he engaged in advanced studies of ion channel electrophysiology and the pharmacology of the central nervous system, topics that have significantly shaped his subsequent research endeavors. His educational foundation laid the groundwork for his future contributions in both academia and the pharmaceutical industry, particularly in the development of novel therapeutic strategies for neurodegenerative diseases, cancer, and metabolic disorders.

Experience

Dr. Stuart Russell Maudsley boasts an extensive career with leadership roles across academia, industry, and government. He is the Principal Investigator at the Maudsley Lab at Moffitt Cancer Center and the co-founder of HeptOME, where he focuses on receptor-targeted therapies for aging-related metabolic diseases. Throughout his career, Dr. Maudsley has held various significant positions, including Adjunct Director at VIB, Vice-Chair at the University of Antwerp’s Department of Biomedical Science, and Principal Investigator at the NIH. He has contributed to numerous international projects, including his work as a Special Science Advisor to the Belgian Superior Health Council. Dr. Maudsley has also led scientific teams at Johnson & Johnson, the U.S. Department of Defense, and the NIH, where he made crucial contributions to drug development and the understanding of receptor pharmacology. His leadership and expertise have resulted in groundbreaking advancements in the pharmacology and therapeutics of complex diseases.

Awards and Honors

Dr. Stuart Russell Maudsley has received numerous prestigious awards and honors throughout his career. Notable recognitions include the 2021 UAntwerpen Seal of Excellence Grant, 2020 Johnson & Johnson Research Grant, and the 2019 FWO Doctoral Research Grant. He has also been honored with the FWO Senior Research Fellows Grant and the UAntwerpen-IOF Industrial Collaboration Research Grant in 2019. His work in molecular pharmacology and receptor biology has led to the receipt of multiple awards from both European and American institutions, including the National Institutes of Health On-the-Spot Award (2011-2013). Dr. Maudsley’s groundbreaking research on neurodegenerative diseases, aging, and metabolic dysfunction has earned him widespread recognition in the scientific community. His scientific excellence and contributions to pharmacology, drug discovery, and biotechnology continue to inspire advancements in the treatment of complex human disorders.

Research Focus

Dr. Stuart Russell Maudsley’s research primarily focuses on receptor pharmacology, with a special emphasis on G-Protein Coupled Receptors (GPCRs) and their role in human disease. His work seeks to identify and develop precision GPCR-targeted therapies for cancer, neurodegenerative disorders, and metabolic diseases such as obesity and aging-related conditions. Through his leadership in both academic labs and the biotech industry, Dr. Maudsley investigates novel biotechnological platforms, including both wet and dry biomedical technologies. He aims to create multidimensional precision medicines that can more effectively treat complex disorders, particularly those related to aging. His current research in the Maudsley Lab centers on the molecular mechanisms that underlie aging and neurodegenerative diseases, as well as the identification of potential therapeutic agents. By exploring the intricate signaling pathways of GPCRs, Dr. Maudsley is paving the way for the development of innovative treatments for diseases that currently lack effective therapies.

Publications Top Notes

  • β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes – Science (1999) 🧬📚
  • BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders – Trends in Neurosciences (2004) 🧠
  • The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women – International Journal of Obesity (2011) 🍏🏃‍♀️
  • Gonadotropin-releasing hormone receptors – Endocrine Reviews (2004) 💊🔬
  • Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma – Free Radical Biology and Medicine (2007) 🏥
  • Caloric restriction and intermittent fasting: two potential diets for successful brain aging – Ageing Research Reviews (2006) 🧠
  • The β2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor – Journal of Biological Chemistry (2000) 🧬🔬

 

 

 

Xiangling Li | Engineering | Best Researcher Award

Dr. Xiangling Li | Engineering | Best Researcher Award

Research Associate, Dartmouth College, United States

Dr. Xiangling Li is an accomplished researcher in biomedical engineering, specializing in micro/nano manufacturing, wearable bioelectronics, and precision medical devices. He currently serves as an Assistant Research Fellow at Dartmouth College, where he focuses on integrating advanced materials and nanotechnology into medical applications. With a Ph.D. from Sun Yat-sen University and postdoctoral research at the University of Southern California, Dr. Li has contributed to cutting-edge innovations in biosensors, drug delivery, and flexible electronics. His groundbreaking research has led to numerous high-impact publications in Advanced Science, Nature Communications, Advanced Functional Materials, and ACS Applied Materials & Interfaces, accumulating hundreds of citations. Dr. Li’s expertise in interdisciplinary research enables the development of next-generation medical devices, improving patient care and diagnostics. His work in integrating electronics, materials science, and life sciences has positioned him as a leader in the field, driving innovations in biomedical engineering and translational medicine.

Profile

Google Scholar
Orcid

Education

Dr. Xiangling Li pursued his academic journey with a strong focus on biomedical engineering and materials science. He earned his Ph.D. in Engineering (Biomedical Engineering) from Sun Yat-sen University, China (2018–2022), where he conducted pioneering research under the guidance of Prof. Xi Xie. His doctoral research focused on developing smart nanomaterials and biosensors for medical applications. After completing his Ph.D., he joined the University of Southern California as a Postdoctoral Fellow (2022–2023) under Prof. Hangbo Zhao, where he advanced his work on flexible bioelectronics and precision medicine. Dr. Li is currently an Assistant Research Fellow at Dartmouth College (since 2023), working with Prof. Wei Ouyang on cutting-edge medical technologies. His diverse educational background has equipped him with expertise in nano/microfabrication, electronic biosensors, and biomedical device engineering, enabling him to make significant contributions to translational medicine and wearable healthcare solutions.

Experience

Dr. Xiangling Li has extensive experience in biomedical engineering, focusing on micro/nano fabrication, biosensors, and advanced medical devices. He is currently an Assistant Research Fellow at Dartmouth College (2023–Present), where he explores novel bioelectronic interfaces for healthcare applications. Previously, he was a Postdoctoral Fellow at the University of Southern California (2022–2023), where he contributed to research on flexible electronic systems for precision medicine. Dr. Li completed his Ph.D. at Sun Yat-sen University (2018–2022), where he developed groundbreaking microfabricated biosensors and drug delivery platforms. His research expertise spans interdisciplinary fields, including wearable diagnostics, nanotechnology-enabled therapeutics, and malleable electronics. With multiple high-impact publications and extensive collaborations across disciplines, Dr. Li’s contributions continue to shape the future of smart medical devices. His experience bridges academia and industry, enabling the development of innovative biomedical solutions that improve patient outcomes and healthcare monitoring.

Research Focus

Dr. Xiangling Li’s research is centered on micro/nano manufacturing technologies for biomedical applications. His work integrates flexible electronics, biosensors, and smart materials to develop next-generation medical devices. He specializes in wearable and implantable bioelectronics, focusing on precision drug delivery, transdermal biosensing, and real-time health monitoring. A key area of his research involves microneedle-based systems for minimally invasive glucose monitoring, intraocular pressure regulation, and intelligent drug release platforms. Additionally, he explores graphene-based biosensors, nanoneedle platforms, and soft bioelectronics for enhanced biomedical applications. His innovations in smart contact lenses, flexible supercapacitors, and biocompatible coatings contribute to the advancement of personalized medicine and point-of-care diagnostics. Dr. Li’s interdisciplinary approach, combining electronics, materials science, and life sciences, drives the development of high-performance biomedical devices. His research holds significant potential for revolutionizing non-invasive diagnostics, therapeutic monitoring, and next-generation wearable healthcare solutions.

Publications 📚

  • A fully integrated closed-loop system based on mesoporous microneedles-iontophoresis for diabetes treatment
  • Intelligent wireless theranostic contact lens for electrical sensing and regulation of intraocular pressure
  • Reduced graphene oxide nanohybrid–assembled microneedles as mini-invasive electrodes for real-time transdermal biosensing
  • Smartphone-powered iontophoresis-microneedle array patch for controlled transdermal delivery
  • Nanoneedle platforms: the many ways to pierce the cell membrane
  • Electrodes derived from carbon fiber-reinforced cellulose nanofiber/multiwalled carbon nanotube hybrid aerogels for high-energy flexible asymmetric supercapacitors
  • Hierarchical graphene/nanorods-based H₂O₂ electrochemical sensor with self-cleaning and anti-biofouling properties
  • Emerging roles of 1D vertical nanostructures in orchestrating immune cell functions
  • Fe₃O₄ nanoparticles embedded in cellulose nanofiber/graphite carbon hybrid aerogels as advanced negative electrodes for flexible asymmetric supercapacitors
  • Wearable and implantable intraocular pressure biosensors: recent progress and future prospects